Compare New York Times Co (NYT) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs 10X Genomics Inc — how do they compare? New York Times Co trades at $64.3 (market cap $10.28B), while 10X Genomics Inc trades at $57.78 (market cap $7.61B). The key difference: New York Times Co is the larger of the two by market cap, and New York Times Co pays a 1.44% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| NYT | TXG | |
|---|---|---|
Market Cap | $10.28B | $7.61B |
Sector | Media | Health |
52-Week High | $85.86 | $58.57 |
52-Week Low | $54.66 | $11.34 |
Enterprise Value | $9.67B | $7.14B |
Dividend Yield | 1.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $64.80, up 1.98% today, with a bearish technical signal despite recent earnings beats. Fundamentals show strong revenue growth to $2.82 billion in 2025 and a net income margin of 13.19%, though digital subscriber growth concerns have pressured the stock. The current P/E ratio is 26.55, above industry averages, reflecting its premium valuation.
The outlook is mixed; solid profitability and a consensus price target of $77.50 suggest upside, but slowing subscriber additions and high valuation pose risks. Investor sentiment is cautious due to recent price weakness, with analysts predominantly holding a 'Hold' rating, indicating a wait-and-see approach for near-term catalysts.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
